Jefferies raised the firm’s price target on Praxis Precision (PRAX) to $450 from $300 and keeps a Buy rating on the shares. Praxis Precision could file two NDAs in early 2026 following positive pivotal EMBOLD’s Cohort 2 interim data for relutrigine in SCN2A/8A and a positive pre-NDA outcome for ulixacaltamide in ET essential tremor, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Praxis Precision Medicines: Promising Epilepsy Portfolio Advances Justify Buy Rating
- Praxis Precision price target raised to $760 from $540 at Guggenheim
- Praxis Precision Medicines Shares RADIANT Study Results
- Praxis Precision price target raised to $500 from $360 at Truist
- Praxis Precision price target raised to $353 from $251 at TD Cowen